New England Journal of Medicine· 2021Q1· Clinical trial

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira et al.

4,661citations
Q1SCImago
2021year

Short summary

Empagliflozin significantly reduced the combined risk of cardiovascular death or hospitalization for heart failure by 21% in patients with preserved ejection fraction heart failure.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine